Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer www.nejm.org/doi/full/10.... phase 3 trial, adding palbociclib to maintenance HER2-targeted🎯 &ET significantly improved progression-free survival in patients with HR+, HER2-+🧬 metastatic #BreastCancer